Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data

Pfizer appears to have used the relabeling of its COX-2 inhibitor Celebrex to add class cardiovascular risk language as an opportunity to renegotiate the placement of safety data